Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2845041 | 0.80 | TNF (0.36) | TDP1MEN1ALDH1A1KMT2A | |
| SCHEMBL1547930 | 0.74 | ALDH1A1 (0.55) | TDP1MEN1ALDH1A1KMT2ACYP2A6 | |
| SCHEMBL172044 | 0.72 | CYP3A4 (0.36) | CYP3A4MAPK1TDP1MEN1ALDH1A1 | |
| SCHEMBL189622 | 0.72 | ALDH1A1 (0.59) | CYP3A4MAPK1TDP1MEN1ALDH1A1 | |
| SCHEMBL14223535 | 0.72 | ALDH1A1 (0.39) | CYP3A4MAPK1TDP1MEN1ALDH1A1 | |
| SCHEMBL16958731 | 0.72 | CYP3A4 (0.42) | CYP3A4MAPK1TDP1MEN1ALDH1A1 | |
| SCHEMBL1547628 | 0.70 | CYP3A4 (0.40) | CYP3A4MAPK1TDP1CYP2A6AHR | |
| SCHEMBL21030288 | 0.69 | CYP3A4 (0.32) | CYP3A4MAPK1ALDH1A1 | |
| SCHEMBL6413858 | 0.67 | CYP2A6 (0.54) | CYP3A4MAPK1TDP1MEN1ALDH1A1 | |
| SCHEMBL29368277 | 0.67 | CYP3A4 (0.62) | CYP3A4MAPK1TDP1ALDH1A1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291730-B2 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-11-06 | — | — | US | disclosed |
| US-20050107609-A1 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY | 2005-05-19 | — | — | US | disclosed |
| US-6838463-B2 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-01-04 | — | — | US | disclosed |
| EP-1366026-B1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040077669-A1 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1366026-A2 | PYRIMIDINE COMPOUNDS AND THEIR USE | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002024663-A2 | PYRIMIDINE COMPOUNDS AND THEIR USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107609-A1 | Pyrimidine compounds and their use | TYMP, TYMS, UMPS | CYP3A4 178/4885MAPK1 2068/4885TDP1 263/4885 |
| US-20040077669-A1 | Pyrimidine compounds and their use | TYMP, TYMS, DPYD | CYP3A4 325/4885MAPK1 1924/4885TDP1 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.